key: cord-0800321-m1pc8ajq authors: Shimabukuro, Tom title: Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer‐BioNTech COVID‐19 vaccine — United States, December 14–23, 2020 date: 2021-02-28 journal: Am J Transplant DOI: 10.1111/ajt.16516 sha: 320bba94c8ecbaa04549ac6c3416d0399cb835f5 doc_id: 800321 cord_uid: m1pc8ajq nan January 15, 2021/70(2);46-51. for Pfizer-BioNTech COVID-19 vaccine to prevent COVID-19, administered as 2 doses separated by 21 days. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine; 1 initial doses were recommended for health care personnel and long-term care facility residents. 2 As of December 23, 2020, a re- vaccines currently authorized in the United States 4 and interim considerations for preparing for the potential management of anaphylaxis. 5 In addition to screening for contraindications and precautions before administering COVID-19 vaccines, vaccine locations should have the necessary supplies available to manage anaphylaxis, should implement postvaccination observation periods, and should immediately treat persons experiencing anaphylaxis signs and symptoms with intramuscular injection of epinephrine. 4, 5 CDC and FDA received notification of suspected anaphylaxis cases through multiple channels, including direct outreach by health care providers and public health officials and reports to VAERS, the national passive surveillance (spontaneous reporting) system for adverse events after immunization, which is jointly operated by CDC and FDA. 6 All notifications of suspected anaphylaxis that came to the attention of CDC or FDA were also captured in VAERS. Early safety monitoring of the Pfizer-BioNTech COVID-19 vaccine has detected 21 cases of anaphylaxis after reported administration Anaphylaxis is a severe, life-threatening allergic reaction that occurs rarely after vaccination. During December 14-23, 2020, monitoring by the Vaccine The findings in this report are subject to at least four limitations. First, the anaphylaxis and nonanaphylaxis allergic reaction case reports were gathered through passive surveillance based on spontaneous reports to VAERS. Spontaneous reporting is subject to reporting biases (including underreporting); however, the reporting efficiency to VAERS for clinically severe adverse events is believed to be high. 9 A second potential source of bias arises from stimulated reporting related to increased public and health care provider awareness of a potential safety concern. Thus, it is possible that intense media attention around the national COVID-19 vaccination program and heightened awareness of reports of anaphylaxis have affected vaccine recipient and health care provider behavior and practices, including elevated concern and anxiety, higher index of suspicion for Project. * https://www.cdc.gov/coron aviru s/2019-ncov/hcp/clini cal-care/lateseque lae.html. † Anaphylaxis and nonanaphylaxis allergic reaction cases with symptom onset occurring later than the day after vaccination (i.e., outside of the 0-1-day risk window) were excluded because of the difficulty in clearly attributing allergic reactions with onset outside this risk window to vaccination. Three of the initial 86 nonanaphylaxis allergic reactions were excluded from the final analysis. § Based on the Code of Federal Regulations, a serious adverse event is defined if one of the following is reported: death, life-threatening illness, hospitalization or prolongation of hospitalization, permanent disability, congenital anomaly, or birth defect. https://www.acces sdata. fda.gov/scrip ts/cdrh/cfdoc s/cfcfr/ cfrse arch.cfm?fr=312.32. ¶ https://www.aaaai.org/about -aaaai/ newsr oom/aller gy-stati stics. The Advisory Committee on Immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine-United States The Advisory Committee on Immunization Practices' interim recommendation for allocating initial supplies of COVID-19 vaccine-United States Vaccine-associated hypersensitivity COVID-19 vaccination: clinical considerations. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS) Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data Hypersensitivity Working Group of the Clinical Immunization Safety Assessment Network. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS The reporting sensitivities of two passive surveillance systems for vaccine adverse events Excess deaths associated with COVID-19, by age and race and ethnicity-United States TA B L E 2 Characteristics of patients with report of anaphylaxis and nonanaphylaxis allergic reactions after receipt of Pfizer-BioNTech COVID-19 vaccine -Vaccine Adverse Events Reporting System (VAERS), United States, December 14-23, 2020 *Three of the initial 86 nonanaphylaxis allergic reaction reports were excluded from the final analysis because symptom onset occurred later than the day after vaccination (i.e., outside of the 0-1-day risk window). †Eleven reports were missing information on time of symptom onset; percentage calculated among 72 patients. §Seven anaphylaxis patients reported a history of a previous anaphylaxis episode, including one after receipt of rabies vaccine and one after receipt of influenza A(H1N1) vaccine.